جست‌وجوی استاد و پژوهشگر

Scott Michael Lindhorstمشاهده پروفایل

استادیار

• Neuro-Oncology
• Medical Oncology
• Brain & Spine Tumors
• +۲ مورد دیگر

Scott Michael Lindhorst, MD, is an Assistant Professor in the Department of Neurosurgery at the Medical University of South Carolina (MUSC) College of Medicine. He holds a dual appointment in the Division of Hematology/Medical Oncology within the Department of Medicine. Dr. Lindhorst specializes in neuro-oncology, focusing on central nervous system lymphomas, gliomas, and meningiomas, while also managing brain metastases through clinical trials. Education: BS in Microbiology from University of Florida (2001), MD from University of South Alabama College of Medicine (2005) Training: Residency in Internal Medicine, Fellowship in Hematology/Medical Oncology (University of Alabama at Birmingham), Fellowship in Neuro-Oncology (Duke University Medical Center) His research centers on immuno-oncology , glioblastoma therapy , and epigenetic cancer treatments , with a strong emphasis on clinical trials for novel therapies. Recent publications explore hypermutation in cancer , immune checkpoint inhibition , and programmed necrosis in glioblastoma . Dr. Lindhorst is board-certified in internal medicine, hematology, medical oncology, and neuro-oncology. Clinical practice includes CNS lymphomas , gliomas , meningiomas , and brain metastases , with dedicated clinical trials to advance treatment options.

Andrea Sottorivaمشاهده پروفایل

استاد

• Cancer Evolution
• Computational Biology
• Genomics
• +۴ مورد دیگر

Andrea Sottoriva is the Head of the Computational Biology Research Centre at Human Technopole , Milan, Italy, and holds the title of Professor of Cancer Genomics and Evolution . His work bridges computational biology, evolutionary theory, and clinical oncology to predict cancer progression and design adaptive treatment strategies. University of Bologna – BSc in Computer Science (2006) University of Amsterdam – MSc in Computational Sciences (2008) University of Cambridge – PhD in Computational Biology (2012) Dr. Sottoriva's research focuses on cancer evolution , applying machine learning and population genetics to decode tumor heterogeneity through multi-omics data. His lab integrates patient-derived organoids and spatial genomics to understand how genetic and epigenetic factors drive cancer progression. The 15 most recent publications demonstrate a consistent emphasis on subclonal dynamics (7/15), computational methods (6/15), and evolutionary modeling (5/15). Key themes include adaptive mutability in colorectal cancer , immune editing in post-transplantation relapses, and deep learning applications for tumor heterogeneity. Scientific recognition includes: Cancer Research UK Future Leaders in Cancer Research Prize (2016) His lab currently trains PhD students and postdoctoral researchers in computational oncology, maintaining a living biobank of patient-derived models while pioneering AI-mechanistic hybrid models for clinical translation.

Peter Parkمشاهده پروفایل

استاد

• Genomics
• Bioinformatics
• Computational Biology
• +۴ مورد دیگر

Peter Park is a Professor of Biomedical Informatics at Harvard Medical School and Director of its Bioinformatics and Integrative Genomics (BIG) PhD program. His research focuses on computational analysis of genomic data, particularly in cancer genomics, somatic mosaicism, and epigenetic mechanisms. He leads major projects like the Somatic Mosaicism across Human Tissues (SMaHT) network and contributes to consortia such as The Cancer Genome Atlas (TCGA) and ENCODE. His work integrates advanced computational methods with clinical applications, aiming to advance precision medicine and understand genetic drivers of disease. Education: B.A. in Applied Mathematics, Harvard University Ph.D. in Applied Mathematics, California Institute of Technology Postdoctoral studies in biostatistics, focusing on molecular biology and genetics Research Interests: His lab develops algorithms for genomic data analysis, including methods for detecting copy number variations, mutational signatures, and structural variations. Key areas include cancer genomics, somatic mosaicism in neurodegenerative diseases, and 4D nucleome structure-function relationships. He emphasizes translational research, applying computational tools to clinical problems like tumor evolution and drug response prediction. Funding & Grants: NIH grants (e.g., R01HG012573, R01CA269805) Funding from Mark Foundation, Simons Foundation, and Chan Zuckerberg Initiative Principal Investigator for multiple collaborative projects Labs & Teams: The Park Lab collaborates with interdisciplinary teams in computational biology, oncology, and neuroscience. Current projects include developing tools for single-cell DNA sequencing analysis and exploring mutational signatures in cancer and neurodegenerative disorders.

• Medical Oncology
• Hematology
• Gastrointestinal Cancers
• +۶ مورد دیگر

Thejal Srikumar, MD , is an Assistant Professor of Medicine in the Department of Medical Oncology and Hematology at Yale School of Medicine. She practices at Smilow Cancer Hospital and Yale Cancer Center in New Haven, specializing in gastrointestinal cancers, particularly in young adults and those with genetic predispositions. She is also affiliated with the Center for Gastrointestinal Cancers, the Early Onset Cancer Program, and the Smilow Cancer Genetics & Prevention Program. Education: MD from University of South Florida Morsani College of Medicine; Executive MPH from Yale School of Public Health (Epidemiology & Health Informatics); Residency and Fellowship in Internal Medicine and Hematology/Oncology at Yale, where she served as Chief Resident and Chief Fellow. Her research focuses on gastrointestinal malignancies, early-onset cancers, and the intersection of cancer, obesity, and imaging biomarkers. She has published on topics including CT-based staging, visceral adiposity, and multimodal treatment for gastric cancer. Her work often involves interdisciplinary collaboration with colleagues in surgery, radiology, and public health. Recent publications highlight her dual commitment to clinical oncology and medical education. She has led initiatives on communication skills training, pharmacology curriculum development, and longitudinal wellness programs for hematology/oncology fellows, reflecting her role as Assistant Program Director of the fellowship program. Scientific Awards: No specific awards listed in the provided text. Dr. Srikumar is actively involved in mentoring and teaching, supervising fellows in clinical and didactic settings. She contributes to curriculum development and professional development initiatives. Her work bridges clinical care, research, and education, with a strong emphasis on improving outcomes for high-risk cancer populations and enhancing training for future oncologists. Labs and Teams: She collaborates with the Breast Medical Oncology Group and other oncology research teams at Yale, though she does not lead a standalone lab. Her work is embedded within the clinical and educational infrastructure of the Hematology/Oncology division.

• DNA Damage and Repair
• Molecular Oncology
• Cancer Biology
• +۳ مورد دیگر

Peter McHugh is Professor of Molecular Oncology at the University of Oxford, serving as Director of Oncology Laboratories at the Weatherall Institute of Molecular Medicine (WIMM) and Head of the DNA Damage and Repair Group within the Department of Oncology. His research focuses on understanding DNA damage and repair mechanisms to elucidate cancer causes and improve treatment strategies. McHugh completed his D.Phil in Biochemistry at the University of Oxford in 1996, following a BSc (Hons) in Biochemistry from UMIST in 1991. His postdoctoral training included positions as a Post-Doctoral Fellow at University College London (1997-2001) and as a Royal Society Research Fellow at UCL (2001-2002). His research program centers on molecular mechanisms of DNA repair pathways, particularly investigating nucleases like SNM1A and repair processes for complex DNA damage including interstrand crosslinks. McHugh's work spans structural biology, biochemical characterization of repair enzymes, and translational applications for cancer therapy. His laboratory employs approaches ranging from single-molecule analysis to cellular and animal models to understand how DNA repair deficiencies contribute to cancer development and how these pathways can be targeted therapeutically. Analysis of his recent publications reveals a consistent focus on DNA-protein crosslink repair, nuclease mechanisms, and the development of targeted cancer therapies. His work demonstrates strong interdisciplinary connections between basic DNA repair mechanisms and clinical oncology applications, with particular emphasis on identifying novel therapeutic targets within DNA repair pathways. Royal Society Research Fellow (2001-2002) As Director of Oncology Laboratories at WIMM and Head of the DNA Damage and Repair Group, Professor McHugh oversees significant research infrastructure and leads a team investigating fundamental mechanisms of genome maintenance. His work has implications for understanding cancer predisposition syndromes and developing targeted therapies that exploit DNA repair deficiencies in cancer cells. His laboratory maintains active collaborations across molecular oncology, structural biology, and translational medicine disciplines. The McHugh Group at the WIMM operates state-of-the-art facilities for DNA repair research, with expertise in biochemical reconstitution of repair pathways, cellular DNA damage response analysis, and development of chemical tools to probe repair mechanisms. The group maintains strong connections with clinical oncology researchers to bridge basic science discoveries with therapeutic applications.

Rona Yaegerمشاهده پروفایل

پزشک-پژوهشگر

• Colorectal Cancer
• Molecular Subsets of Cancer
• BRAF Mutations
• +۶ مورد دیگر

Rona Yaeger, MD is a Gastrointestinal Medical Oncologist and Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center, specializing in treating cancers of the colon, rectum, anal squamous cell cancer, carcinoid tumors, and other gastrointestinal tract cancers. Dr. Yaeger completed her MD at New York University, followed by an Internal Medicine residency at Columbia University Medical Center, and fellowships in Medical Oncology at Memorial Sloan Kettering Cancer Center and Medicine at Weill Cornell Medical College. She is board certified in Internal Medicine and Medical Oncology. Her clinical and laboratory research centers on understanding molecular subsets of colorectal cancer and developing new therapies based on this understanding, with a particular focus on colorectal tumors with mutations in the BRAF or RAS genes. She leads the clinical trial program for colorectal tumors that harbor BRAF mutations at MSKCC. Dr. Yaeger's work bridges clinical practice and laboratory research, aiming to use insights from cancer cell biology to guide patient care and develop more rationally designed clinical trials. Her research portfolio demonstrates a strong focus on precision oncology, particularly in the development of targeted therapies for molecularly defined subsets of gastrointestinal cancers. Recent publications highlight her leadership in clinical trials for BRAF-mutated colorectal cancer, KRAS-targeted therapies, and innovative approaches to organ preservation in rectal cancer treatment. Dr. Yaeger serves as an investigator for multiple clinical trials, particularly those focused on molecularly targeted therapies for gastrointestinal cancers with specific genetic mutations. Her work has contributed significantly to establishing new standards of care for patients with BRAF V600E-mutant metastatic colorectal cancer. As a physician-scientist at Memorial Sloan Kettering, Dr. Yaeger is part of a team that integrates cutting-edge research with clinical care, contributing to the development of novel therapeutic approaches for patients with gastrointestinal malignancies.

• Oncology
• Immunotherapy
• Clinical Trials
• +۳ مورد دیگر

Dr Michelle Cummins is a researcher specializing in oncology and clinical trials, with a focus on immuno-oncology, cancer biomarkers, and genomic profiling. Her work spans multiple cancer types including colorectal, endometrial, lung, and mesothelioma, with a strong emphasis on translational research and drug development. She collaborates extensively with groups like the Australasian Gastro-Intestinal Trials Group (AGITG) and ANZGOG, contributing to Phase II and III clinical trials evaluating novel therapies such as durvalumab, tremelimumab, and bevacizumab. Key areas of interest include biomarker discovery (e.g., PD-L1, VEGF, and cell-free DNA), molecular mechanisms of cancer response, and the application of genomic profiling in personalized treatment strategies. Her research also extends to signal transduction pathways in epithelial cells, particularly involving G-protein coupled receptors and calcium signaling mechanisms. Dr Cummins has been involved in landmark studies such as the MAX trial (colorectal cancer therapy), the PHAEDRA trial (endometrial carcinoma immunotherapy), and the ASPiRATION cohort study (lung cancer genomics). Her recent work explores the coupling of tumor and peripheral blood biomarkers in chemoimmunotherapy, reflecting her commitment to advancing precision medicine in oncology. Dr Cummins' contributions include over 20 peer-reviewed publications, with a focus on high-impact journals in oncology, immunotherapy, and clinical research. Her work bridges basic science and clinical application, aiming to improve patient outcomes through evidence-based interventions and innovative trial designs.

• Radiation Oncology
• Gynecologic Malignancies
• Brachytherapy
• +۵ مورد دیگر

Shari Damast, MD is a Professor of Therapeutic Radiology at Yale School of Medicine, serving as Vice Chair for Brachytherapy and Chief of the Gynecologic Radiotherapy Program. She specializes in radiation oncology for gynecologic malignancies, including cervical, uterine, and vulvar cancers, with a focus on brachytherapy and improving patient quality of life. Her work integrates modern techniques like image-guided radiation and addresses sexual health concerns post-treatment. Education & Training: Residency in Radiation Oncology: Memorial Sloan Kettering Cancer Center (2011) Internship in Internal Medicine: Beth Israel Medical Center (2007) MD: Weill Cornell Medical College (2006) BS: Yale University (2002) Research Interests: Dr. Damast’s research emphasizes optimizing brachytherapy techniques, studying prognostic factors in endometrial and cervical cancers, and mitigating treatment side effects. Key topics include MLH1 promoter hypermethylation’s role in endometrial cancer outcomes, vaginal stenosis prevention, and patient-centered care innovations. Publications Overview: Her 15 most recent articles (2022–2024) focus on brachytherapy techniques, radiation dosimetry, genetic biomarkers in cancer prognosis, and clinical guidelines for vulvar and cervical cancers. They reflect a blend of translational and clinical research aimed at enhancing treatment efficacy and patient experience. Awards & Recognition: Yale Cancer Center Award for Clinical Excellence (2021) ARRO Educator of the Year Award (2019–2020) YNHH/Smilow Cancer Hospital Luminary Award of Excellence (2019) ABR Volunteer Service Award (2019) Grants & Mentorship: Dr. Damast collaborates on multidisciplinary teams and leads initiatives to advance brachytherapy education. She mentors residents and fellows in radiation oncology, emphasizing patient-centered care and innovative techniques. Labs & Affiliations: She contributes to the Yale Cancer Center and directs the Gynecologic Radiotherapy Program, fostering a collaborative environment for clinical and translational research.

Alan Waldmanمشاهده پروفایل

استاد

• Cancer Biology
• Biology of Cellular Stress
• Homologous Recombination
• +۲ مورد دیگر

Alan Waldman is a Professor in the Department of Biological Sciences at the University of South Carolina's College of Arts and Sciences. His research focuses on homologous recombination, DNA repair mechanisms, and their implications in cancer biology and genomic instability. He has pioneered experimental systems to study double-strand break repair and sequence divergence tolerance in mammalian chromosomes. Cancer Biology Biology of Cellular Stress Homologous Recombination DNA Repair Genome Stability Dr. Waldman's work explores how mammalian cells maintain genetic fidelity through stringent homology requirements, yet allow recombination under pathological conditions like cancer or aging. His recent studies investigate the role of proteins such as progerin and Bloom helicase in modulating repair pathways. Analysis of his 15 most recent articles reveals trends in understanding DNA repair under stress, mismatch tolerance, and the interplay between aging proteins and genomic instability. Key themes include double-strand break dynamics, chemotherapeutic responses, and recombination errors in disease contexts.

Marco Gerlingerمشاهده پروفایل

استاد

• Cancer Evolution
• Cancer Genomics
• Cancer Immunology
• +۴ مورد دیگر

Professor Marco Gerlinger serves as Consultant Medical Oncologist and Director of GI Cancer Research at St. Bartholomew's Hospital, leading the Centre for Tumour Biology research group. His work focuses on gastrointestinal malignancies, particularly colorectal and gastro-oesophageal cancers, with emphasis on cancer evolution, therapy resistance mechanisms, and novel immunotherapeutic approaches. His research spans Cancer Evolution , Cancer Genomics , and Cancer Immunology , investigating how drug resistance develops in tumors and how treatment sensitivity can be predicted. This work directly informs clinical trials for early-stage and metastatic gastrointestinal cancers, with significant contributions to understanding tumor heterogeneity and immune landscape dynamics. Recent publications demonstrate consistent focus on genomic determinants of therapy resistance, neoantigen landscapes in colorectal cancer, and evolutionary patterns in gastro-oesophageal tumors. His studies bridge fundamental cancer biology with clinical applications in immunotherapy and targeted drug development, particularly examining intratumor heterogeneity and immune microenvironment interactions. Key recognitions include: Fellow of the Royal College of Physicians (FRCP) ERC Grant (2019) for 'Deciphering and predicting the evolution of cancer cell populations' As Group Leader, he directs a multidisciplinary team conducting translational research supported by major funding including a €2 million ERC grant (2019-2024). He actively contributes to clinical trial design and serves on scientific committees for AACR, ASCO, and ESMO conferences. His laboratory at the Centre for Tumour Biology employs integrated genomic, transcriptomic, and immunological approaches to study tumor evolution during therapy, with current projects focused on predicting resistance mechanisms and developing novel combination treatments for gastrointestinal cancers.

Myron Evansمشاهده پروفایل

استادیار

• Pediatric Oncology
• Brain Tumor Research
• Developmental Oncology
• +۴ مورد دیگر

Myron Evans, PhD is an Assistant Professor in the Department of Pediatrics at the University of Washington School of Medicine. He serves as a Principal Investigator at Seattle Children's Research Institute's Ben Towne Center for Childhood Cancer and Blood Disorders Research and is an Affiliate Assistant Member at the Fred Hutch Cancer Center in the Human Biology Division. Dr. Evans joined Seattle Children's in 2021 after completing postdoctoral training at St. Jude Children's Research Hospital. Dr. Evans is a basic and translational scientist whose research focuses on understanding the mechanisms underlying both normal brain development and tumor initiation/progression in pediatric central nervous system (CNS) tumors, such as medulloblastoma and diffuse midline glioma. His lab specializes in developmental oncology, studying the epigenetic regulation of CNS development in the post-natal mammalian brain and how these epigenetic mechanisms become deregulated to contribute to pediatric brain tumors. The ultimate goal of his research is to identify tumor-specific vulnerabilities that can be targeted for new therapies while sparing normal developing brain cells. Dr. Evans' recent publications show a clear research trajectory focused on pediatric brain tumors, particularly medulloblastoma and diffuse intrinsic pontine glioma (DIPG). His work spans multiple approaches including CAR T cell immunotherapy, epigenetic regulation, nucleotide metabolism targeting, and RNA binding protein function. A significant portion of his recent work explores combination therapies to overcome treatment resistance in these aggressive pediatric cancers. His publications frequently investigate how to target MYC-amplified medulloblastoma, which represents the most deadly subgroup with less than 50% five-year survival rates. As a diversity advocate and champion for children with cancer, Dr. Evans leads the Myron Evans Lab at Seattle Children's Research Institute, which is dedicated to understanding why children get brain tumors and which mutations drive tumor formation. The lab combines 'a love of science, passion, and creativity (and a strong cup of coffee)' to bring hope to patients and their families, with the ultimate goal of developing more targeted brain tumor treatments with fewer side effects.

• Genetics
• Translational Genomics
• Neurodegenerative Diseases
• +۷ مورد دیگر

Arturo Lopez Castel is an Assistant Professor in the Department of Genetics at the Faculty of Biological Sciences, Universitat de València, where he is a key member of the Human Translational Genomics research group and affiliated with the Institute of Biotechnology and Biomedicine (BIOTECMED). His work bridges fundamental genetic mechanisms with translational applications in neuromuscular disorders. His research centers on the molecular basis of nucleotide repeat expansion diseases, especially myotonic dystrophy types 1 and 2. Using Drosophila melanogaster as a model organism, he investigates genomic instability, DNA repair deficiencies, and RNA toxicity mechanisms. His studies extend to patient-derived cell lines and mouse models, enabling a comprehensive approach from bench to bedside. Key areas include CTG/CAG repeat instability, epigenetic modifications like CpG methylation, and the role of microRNAs in muscle atrophy. Analysis of his recent publications reveals a strong trajectory in both mechanistic and therapeutic research. He has pioneered in vivo screening platforms, explored natural compounds such as boldine and stephanantherine for treatment, and contributed to understanding parent-of-origin effects in congenital transmission. His work integrates omics technologies and molecular pathology to identify novel biomarkers and therapeutic targets. While no scientific awards are mentioned in the provided text, his sustained publication record in high-impact areas underscores his contributions to the field. He has supervised thesis work and is actively involved in drug development pipelines for myotonic dystrophy, reflecting a commitment to both academic mentorship and clinical translation. Dr. Lopez Castel leads research within the GT Human Translational Genomics group, leveraging collaborative networks and multidisciplinary approaches to tackle complex genetic disorders. His lab combines genetic models, molecular assays, and pharmacological testing to advance understanding and treatment of repeat expansion diseases.

• Clinical Genetics
• Cancer Genetics
• Genomic Screening
• +۴ مورد دیگر

Thomas van Overeem Hansen is a Clinical Professor in the Department of Clinical Medicine, specializing in Clinical Genetics at the University of Copenhagen. His academic work bridges clinical medicine and genetic research with a focus on cancer genetics and genomic diagnostics. His primary research interests include: Clinical Genetics and Genomic Medicine Cancer Genetics and Hereditary Syndromes Variant Interpretation and Molecular Diagnostics Genomic Screening Methodologies Dr. van Overeem Hansen's publication record demonstrates expertise across multiple domains of clinical genetics, with particular emphasis on hereditary cancer syndromes including colorectal cancer, breast cancer, and pediatric cancer genetics. His research spans clinical case reports, large-scale cohort studies, and methodological developments in genomic analysis. He frequently collaborates with multidisciplinary teams across medical specialties to advance understanding of genetic contributions to disease pathogenesis and clinical management. His work has been cited in academic literature and mentioned across various academic social media platforms, reflecting engagement with the broader scientific community. The distribution of his publications shows consistent research productivity with articles appearing in high-impact journals spanning genetics, oncology, and clinical medicine. Dr. van Overeem Hansen's research has direct clinical applications in cancer risk assessment, genetic counseling, and personalized medicine approaches, contributing to improved diagnostic accuracy and treatment strategies for patients with hereditary conditions.

Fernando Benavidesمشاهده پروفایل

استاد

• Mouse Genetics
• Genetic Engineering
• Cancer Biology
• +۳ مورد دیگر

Fernando Benavides, DVM, PhD, DACLAM is a Professor in the Department of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center (Smithville, TX). He also serves as an Associate Faculty Member in the Graduate School of Biomedical Sciences (Houston, TX) and holds dual appointments in related departments. As Director of the Laboratory Animal Genetics Services, he specializes in genetic monitoring of inbred rodent strains, authentication of mouse cell lines, and speed congenic projects to transfer genes to defined genetic backgrounds. His expertise spans positional cloning of spontaneous mutations, complex breeding schemes, and international rodent genetic consultation. Research Focus : Dr. Benavides' work centers on mouse genetics and laboratory animal science, with applications to cancer research. Key areas include genetic quality control of rodent models, development of standardized populations, and mechanistic studies using genetically engineered mice. He has described novel mouse models and contributed to guidelines for genetic reporting (LAG-R) and strain nomenclature. Professional Contributions : His leadership in rodent genetics standards has impacted global research practices. Projects include genetic background characterization via next-generation sequencing and resolving issues like viral contamination in rodent colonies. He collaborates internationally to ensure genetic integrity of experimental models.

• Colorectal Surgery
• Minimally Invasive Surgery
• Inflammatory Bowel Disease
• +۳ مورد دیگر

Vikram Reddy, MD, PhD, MBA, is an Associate Professor of Surgery (Colon and Rectal) and Chief of Colon and Rectal Surgery at Yale School of Medicine. He specializes in advanced minimally invasive colorectal surgeries, including laparoscopic and robotic techniques for cancer, inflammatory bowel disease, and complex gastrointestinal conditions. His clinical expertise includes sphincter-preserving rectal cancer surgery, transanal endoscopic microsurgery (TEMS), and corrective pouch procedures for failed ileal pouch-anal anastomosis. Dr. Reddy’s academic training includes an MD and PhD from the Medical College of Georgia (2003), residency at Yale-New Haven Hospital (2008), and a fellowship at the University of Medicine & Dentistry of New Jersey (2009). He holds an MBA from Yale University (2021). His research focuses on improving surgical outcomes, reducing postoperative complications like low anterior resection syndrome, and optimizing care for inflammatory bowel disease patients. He collaborates with multidisciplinary teams in programs such as the Inflammatory Bowel Disease Program and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program. Awarded Connecticut Magazine’s Top Docs in 2015 and 2016, Dr. Reddy is a Fellow of the American College of Surgeons (FACS) and the American Society of Colon and Rectal Surgeons (FASCRS). His clinical practice emphasizes patient-centered care and innovative surgical techniques to preserve quality of life.